Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select... Read More

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological... Read More

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025 Fireside Chat: 11:40 AM ET Event:... Read More

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IH ORX142 on track to initiate first-in-human studies for... Read More

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IH ORX142 in IND-enabling studies for the... Read More

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1),... Read More

BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025 Fireside Chat: 1:00 PM ET Event:... Read More

BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and... Read More

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of... Read More

BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: November 13, 2024 Location: Boston, MA Fireside... Read More

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are... Read More

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per... Read More

BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by... Read More

2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT) Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date 1 PK profile supports once-daily dosing Company plans to rapidly... Read More

BOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster... Read More

BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22 nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05... Read More

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological,... Read More

BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business... Read More

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET... Read More

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in... Read More

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The... Read More

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by... Read More

BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug... Read More

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024 Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody ® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and... Read More

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44 th Annual Health Care Conference in Boston, MA. A fireside chat is scheduled for Tuesday, March 5 th at 2:50 PM ET. The live... Read More

BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17 th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in... Read More

BOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim’s 6 th Annual Biotechnology Conference Date: February 7, 2024 Location: NY, NY Fireside... Read More

BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Saurabh Saha MD PhD, Chief Executive Officer of Centessa, is scheduled to present at the conference on... Read More

Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC: Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observed Poster presentation at American Society of Hematology (ASH) Annual meeting Registrational PRESent-2 and PRESent-3 studies of SerpinPC in hemophilia B are... Read More

SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in... Read More

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during a poster session at the 65 th American Society of Hematology (ASH) Annual Meeting in San Diego, CA on December 10, 2023.... Read More

BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The dosing phase of PRESent-3 follows a minimum... Read More

BOSTON and LONDON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies London Healthcare Conference Date: November 15, 2023 Location: London Fireside Chat: 10:30... Read More

Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) ORX750 advancing in IND-enabling studies; Clinical proof of concept data planned for 2024 BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are... Read More

BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development,... Read More

BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference, including a fireside chat on Tuesday, September 12, 2023 at 4:15 p.m. ET. The... Read More

BOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidate, will be featured in an oral presentation at the World Sleep Congress being held on October 20-25, 2023,... Read More

Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B Enrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody ® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at... Read More

BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-2 study of SerpinPC for the treatment of hemophilia B without inhibitors. The dosing phase of PRESent-2 follows a minimum... Read More

BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: Friday, June 9, 2023 Location: New York, NY Fireside... Read More

BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the... Read More

Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody ® to treat solid tumors Conducting IND enabling activities for ORX750, an orally administered, selective... Read More

Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody ® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023 Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist, as product candidate with the... Read More

BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Genomic Medicines and Rare Disease Days Date: Monday, April 3, 2023 Location:... Read More

BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines. “This is an exciting time for Centessa as we are... Read More

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for... Read More

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast... Read More

BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a first-in-human, clinical trial of... Read More

Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93% reduction in median ABR for both all-bleeds and spontaneous joint bleeds in highest dose tested No thromboembolic events or treatment-related sustained elevations of D-dimer observed Pivotal program for SerpinPC in hemophilia B... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies London Healthcare Conference Date: Thursday, November 17, 2022 Location: London, UK Fireside Chat: 10:55 AM GMT Event: Evercore ISI... Read More

Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) Company recognizes World Narcolepsy Day on September 22 nd Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research... Read More

Registrational studies planned to start in 4Q 2022 Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced that the U.S. Food and Drug Administration (FDA) has... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced non-clinical pharmacokinetic (PK) and safety data in non-human primates (NHPs) for LB101 (PD-L1xCD47), its first LockBody® candidate for solid tumors. Findings from these data... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that members of its management team will participate in the following investor conferences: Event: Morgan Stanley 20th Annual Global Healthcare Conference Date: Monday, September 12,... Read More

Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 Oncology pipeline advancing with novel LockBody® technology Announces discontinuation of ZF874 for AATD Multiple clinical PoC readouts expected across pipeline over next two years Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. “We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. In... Read More

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences: Event : Jefferies... Read More